Thermo Fisher Scientific Inc. (NYSE: TMO) has completed its acquisition of PPD, Inc. (NASDAQ: PPD), a global provider of clinical research services to biopharma and biotech industries, for $17.4 billion.

The combined firm will offer a comprehensive suite of services across clinical development including scientific discovery; assessing safety, efficacy, and healthcare outcomes; managing clinical trial logistics; and the development and manufacturing of a drug product.

“We are very excited to officially welcome our PPD colleagues to Thermo Fisher Scientific,” said Marc Casper, chairman, president and chief executive officer of Thermo Fisher Scientific. “Expanding our value proposition for our biotech and pharmaceutical customers with the addition of PPD’s leading clinical research services advances our work in bringing life-changing therapies to market, benefitting patients around the world.”